Abstract:Dear Editor, It was proposed by Haider and Ashraf1 that cytokine and growth factor mediated mobilization of endogenous mesenchymal stem cells from their bone marrow niches for homing into the infarcted myocardium could be a better therapeutic strategy than the explantation and subsequent injection of these cells (either autologous or from a donated allogenic source) directly into the damaged heart.2 Besides being less invasive to the patient, it was argued that this approach would obviate the need for ex vivo processing of the putative stem cells, which could in turn reduce the risk of nonspecific differentiation into undesired lineages at the transplantation site.3–5 Nevertheless, such an approach could be severely hampered by the age related decline in the regenerative capacity of the putative mesenchymal stem cell population within the bone marrow, as has been demonstrated by a number of studies.6,7 It must be remembered that the overwhelming majority of myocardial infarct cases occur in the older segment of the population.8 Quarto and colleagues6 demonstrated in a rat model that there was an age associated decline in the ability of marrow stromal cells to repair bone, which could be the underlying cause of age related osteodegenerative diseases. Subsequently, D’Ippolito and colleagues7 reported a similar finding with the human model. This would be expected because, with increasing age, the putative mesenchymal stem cell population within the bone marrow would have gone through more rounds of cell division, in addition to having been exposed to free radicals and metabolic toxins over a longer lifespan. Hence it is no surprise that there is a gradual decline in their regenerative capacity with increasing age. Although there have been no studies to date that have conclusively demonstrated an age associated decline in the capacity of bone marrow cells to repair the infarcted heart, we could make such a conjecture based upon extrapolation from the bone repair model.6,7 The obvious solution to overcome this age related decline in regenerative capacity would be to look at donated allogenic sources of stem cells for myocardial repair. In this regard, human embryonic stem (hES) cells or their differentiated progenies would hold much promise because these potentially represent an abundant and readily available source of transplantable cells. Recently, Zandstra and colleagues9 successfully developed a scalable, robust, and reproducible process for obtaining purified cardiomyocytes from hES cells. Nevertheless, the immunologic barrier10 probably represents the most formidable challenge to the allogenic transplantation of hES cells or their differentiated progenies into the infarcted myocardium. It is hoped that this could somehow be overcome in the near future. Boon Chin Heng* Eugene Kwang-Wei Sim† Tong Cao* *Stem Cell Laboratory, Faculty of Dentistry, †Department of Surgery, Faculty of Medicine National University of Singapore.

Cell Transplantation with a Catheter‐based Approach: an Efficient Method for the Treatment of Heart Failure with Multiple Lesions

Combining Transfusion of Stem/progenitor Cells into the Peripheral Circulation with Localized Transplantation in Situ at the Site of Tissue/organ Damage: A Possible Strategy to Optimize the Efficacy of Stem Cell Transplantation Therapy

Reply to Letter from Drs. Haider and Ashraf

Homing of intravenously infused embryonic stem cell- derived cells to injured hearts after myocardial infarction

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Human Bone Marrow-Derived Mesenchymal Stem Cells Transplanted into Damaged Rabbit Heart to Improve Heart Function.

Angiotensin Receptor Type 2 Stimulation Increases the Migration of Bone-Marrow Mononuclear Cells into the Infarcted Myocardium and Improves Heart Function

Improvement of Cardiac Function by Transplanting Autologous Mononuclear Bone Marrow Cells into Myocardial Infarction Scar and the Periphery

The Recent Advances in Cell Delivery Approaches, Biochemical and Engineering Procedures of Cell Therapy Applied to Coronary Heart Disease

Current Research on Cell Transplantation for Cardiovascular Diseases

[A Prospective, Randomized, Controlled Trial of Autologous Mesenchymal Stem Cells Transplantation for Dilated Cardiomyopathy].

Abstract 248: Comparison Of Transplantation Of Bone Marrow-derived Stem Cells, Adipose-derived Stem Cells And Endometrium- Derived Stem Cells In The Infarcted Heart

A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery.

Cellular cardiomyoplasty for a patient with heart failure.

Cellular Cardiomyoplasty Using Different Stem Cells in a Single Center

Transplantation of Embryonic Stem Cells Improves Cardiac Function in Postinfarcted Rats

Cellular Cardiomyoplasty: a Preliminary Clinical Report.

[Stem cell therapy for cardiovascular diseases. Experiences in Düsseldorf]

Stem cell transplantation therapy for angiocardiopathy:Clinical progress in China

Trials and tribulations of cell therapy for heart failure: an update on ongoing trials

Clinical cellular cardiomyoplasty: technical considerations.